IP Library Granted Patent US 12,576,087
Granted Patent B2
US 12,576,087 · App. 17/268,995 · Granted Mar 17, 2026

Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Inventors: Dane Clausen (Rahway, NJ); Xavier Fradera (Brookline, MA); Liangqin Guo (Monroe, NJ); Yongxin Han (Needham, MA); Shuwen He (Fanwood, NJ); Xianhai Huang (Warren, NJ); Joseph Kozlowski (Princeton, NJ); Guoqing Li (Belle Mead, NJ); Jongwon Lim (Lexington, MA); Theodore A. Martinot (Southborough, MA); Alexander Pasternak (Jamaica Plain, MA); Nunzio Sciammetta (Sudbury, MA); Andreas Verras (New York, NY); Li Xiao (Cranbury, NJ); Wensheng Yu (Edison, NJ); Rui Zhang (Plainsboro, NJ)
Assignee: Merck Sharp & Dohme LLC
A61K31/5377A61K31/454A61K31/4545A61K31/46A61K31/496A61K45/06C07D401/06C07D401/14C07D413/14C07D451/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,087
App. No.
17/268,995
Granted
Mar 17, 2026
Kind
B2
Abstract

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Claims (337)

1 . A compound of formula (I), or a pharmaceutically acceptable salt thereof:

wherein:

m is 0 or 1; n is 0, 1 or 2;

X is selected from (1) —O—, (2) —CR d R d —, and (3) —CH 2 —O—, wherein each occurrence of R d is independently selected from: (1) hydrogen and (2) halogen;

R a is selected from: (1) hydrogen and (2) C 1-6 alkyl;

each occurrence of R b is independently selected from: (1) hydrogen, (2) halogen and (3) C 1-6 alkyl;

or alternatively, two R b groups on the same ring carbon form a 3-4 membered spiro cyclopropyl;

or alternatively, two R b groups on adjacent ring carbons together with the two ring carbons form a fused cyclopropyl;

or alternatively, two R b groups on non-adjacent ring carbons together with the nitrogen ring atom form a 5-6 membered nitrogen-containing bridged heterocyclyl wherein the heterocyclyl contains no additional hetero atom;

R c is selected from: (1) hydrogen and (2) halogen;

R 1 and R 2 together with the carbons to which they are attached form a 5-7 membered carbocyclyl selected from:

(1) a mono-cyclic 5-membered ring; and

(2) a bicyclic fused ring containing a 5-membered ring fused to a 3-membered ring,

R is selected from (1) —O—C 1-6 alkyl, (2) C 1-6 alkyl optionally substituted with —OH and (3)

each of R 3 and R 4 is independently selected from: (1) hydrogen and (2) C 1-6 alkyl;

or alternatively, R 3 and R 4 together with the nitrogen to which they are attached form a 5-6 membered heterocyclyl containing the one nitrogen to which they are attached and zero to two additional hetero atoms independently selected from N, S and O, wherein the heterocyclyl is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) —OH,

(c) C 1-6 alkyl, optionally substituted with one to four substituents independently selected from (a) —OH, (b) halogen and (c) —C(O)—NHR e , wherein R e is selected from (i) hydrogen and (ii) C 1-6 alkyl,

(d) —O—C 1-6 alkyl, optionally substituted with one to four substituents independently selected from (a) —OH and (b) halogen,

(e) —NHR f , wherein R f is selected from (i) hydrogen, (ii) C 1-6 alkyl and (iii) —C(O)—C 1-6 alkyl, and

(f) —C(O)—C 1-6 alkyl, optionally substituted with one to four substituents independently selected from (a) —OH and (b) halogen; and

R 5 is selected from (1) carbocyclyl and (2) heterocyclyl, wherein each of the carbocyclyl and heterocyclyl is optionally substituted with one to three substituents independently selected from:

(a) halogen,

(b) C 1-6 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-6 alkyl, optionally substituted with one to four halogens, and

(d) —CN.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

X is selected from (1) —O—, and (2) —CF 2 —, and

R a is hydrogen.

3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

each occurrence of R b is independently selected from: (1) hydrogen, (2) fluoro and (3) C 1-4 alkyl.

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R c is selected from: (1) hydrogen and (2) fluoro.

5 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R is selected from (1) —O—C 1-4 alkyl, (2) C 1-4 alkyl optionally substituted with —OH and (3)

 and

each of R 3 and R 4 is independently selected from: (1) hydrogen and (2) C 1-4 alkyl;

or alternatively, R 3 and R 4 together with the nitrogen to which they are attached form a 5-6 membered non-aromatic heterocyclyl containing the one nitrogen to which they are attached and zero to one additional hetero atom independently selected from N, S and O, wherein the heterocyclyl is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) —OH,

(c) C 1-4 alkyl, optionally substituted with one to four substituents independently selected from (a) —OH, (b) halogen and (c) —C(O)—NR e , wherein R e is selected from (i) hydrogen and (ii) C 1-4 alkyl,

(d) —O—C 1-4 alkyl, optionally substituted with one to four substituents independently selected from (a) —OH and (b) halogen,

(e) —NHR f , wherein R f is selected from (i) hydrogen, (ii) C 1-4 alkyl and (iii) —C(O)—C 1-4 alkyl, and

(f) —C(O)—C 1-4 alkyl, optionally substituted with one to four substituents independently selected from (a) —OH and (b) halogen.

6 . The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein:

R is selected from (1) —O—C 1-4 alkyl and (2)

 and

R 3 and R 4 together with the nitrogen to which they are attached form a 5-6 membered heterocyclyl containing one N and zero to one additional hetero atom independently selected from N, S and O, wherein the heterocyclyl is optionally substituted with one to four substituents independently selected from:

(a) fluoro,

(b) —OH,

(c) C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH, (b) halogen and (c) —C(O)—NH 2 ,

(d) —O—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen,

(e) —NHR f , wherein R f is selected from (i) hydrogen, (ii) methyl, (iii) ethyl and (iv) —C(O)—CH 3 , and

(f) —C(O)—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen.

7 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 5 is selected from (1) carbocyclyl and (2) heterocyclyl,

wherein the carbocyclyl of (1) is selected from (a) C 3-6 cycloalkyl, (b) phenyl, (c) naphthyl and (d) 2,3-dihydro-1H-indenyl;

wherein the heterocyclyl of (2) is selected from (a) pyridinyl, (b) pyrimidinyl, (c) isoquinolinyl and (d) benzo[d]isothiazolyl; and

wherein each of the carbocyclyl and heterocyclyl is optionally substituted with one to three substituents independently selected from:

(a) halogen,

(b) C 1-4 alkyl, optionally substituted with one to four halogens, and

(c) —CN.

8 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, of formula (Ib):

wherein:

m is 0 or 1; n is 0, 1 or 2; p is 1;

X is selected from (1) —O and (2) —CF 2 ;

R a is selected from: (1) hydrogen and (2) C 1-4 alkyl;

each occurrence of R b is independently selected from: (1) hydrogen, (2) fluoro and (3) C 1-4 alkyl;

or alternatively, two R b groups on the same ring carbon form a spiro cyclopropyl;

or alternatively, two R b groups on adjacent ring carbons together with the two ring carbons form a fused cyclopropyl;

or alternatively, two R b groups on non-adjacent ring carbons together with the nitrogen ring atom form a 5-6 membered nitrogen-containing bridged heterocyclyl wherein the heterocyclyl contains no additional hetero atom;

R c is selected from: (1) hydrogen and (2) halogen;

R 3 and R 4 together with the nitrogen to which they are attached form a 5-6 membered heterocyclyl containing the one nitrogen to which they are attached and zero to one additional hetero atom independently selected from N, S and O, wherein the heterocyclyl is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) —OH,

(c) C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH, (b) halogen and (c) —C(O)—NH 2 ,

(d) —O—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen,

(e) —NHR f , wherein R f is selected from (i) hydrogen, (ii) methyl, (iii) ethyl and (iv) —C(O)—CH 3 , and

(f) —C(O)—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen; and

R 5 is selected from (1) carbocyclyl and (2) heterocyclyl,

wherein the carbocyclyl of (1) is selected from (a) C 3-6 cycloalkyl, (b) phenyl, (c) naphthyl and (d) 2,3-dihydro-1H-indenyl;

wherein the heterocyclyl of (2) is selected from furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, naphthyridinyl, phthalazinyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, quinazolinyl, isoquinolinyl and benzo[d]isothiazolyl; and

wherein each of the carbocyclyl and heterocyclyl is optionally substituted with one to three substituents independently selected from:

(a) halogen,

(b) C 1-4 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-4 alkyl, optionally substituted with one to four halogens and

(d) —CN.

9 . The compound of claim 8 , or a pharmaceutically acceptable salt thereof:

wherein:

m is 1; n is 1; p is 1;

X is selected from (1) —O— and (2) —CF 2 ;

R a is hydrogen;

each occurrence of R b is independently selected from: (1) hydrogen, (2) fluoro, (3) methyl and (4) ethyl;

or alternatively, two R b groups on the same ring carbon form a spiro cyclopropyl;

or alternatively, two R b groups on adjacent ring carbons together with the two ring carbons form a fused cyclopropyl;

or alternatively, two R b groups on non-adjacent ring carbons together with the nitrogen ring atom form a 5-6 membered nitrogen-containing bridged heterocyclyl wherein the heterocyclyl contains no additional hetero atom;

R c is selected from: (1) hydrogen and (2) fluoro;

R 3 and R 4 together with the nitrogen to which they are attached form a 5-6 membered non-aromatic heterocyclyl containing the one nitrogen to which they are attached and zero to one additional hetero atom independently selected from N and O, wherein the heterocyclyl is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) —OH,

(c) C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH, (b) halogen and (c) —C(O)—NH 2 ,

(d) —O—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen,

(e) —NHR f , wherein R f is selected from (i) hydrogen, (ii) methyl, (iii) ethyl and (iv) —C(O)—CH 3 , and

(f) —C(O)—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen; and

R 5 is selected from (1) carbocyclyl and (2) heterocyclyl,

wherein the carbocyclyl of (1) is selected from (a) C 3-6 cycloalkyl, (b) phenyl, (c) naphthyl and (d) 2,3-dihydro-1H-indenyl;

wherein the heterocyclyl of (2) is selected from (a) pyridinyl, (b) pyrimidinyl, (c) isoquinolinyl and (d) benzo[d]isothiazolyl; and

wherein each of the carbocyclyl and heterocyclyl is optionally substituted with one to three substituents independently selected from:

(a) halogen,

(b) methyl, optionally substituted with one to three halogens,

(c) —OCH 3 ,

(d) —OCF 3 and

(e) —CN.

10 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, of formula (Ic):

wherein:

n is 0 or 1;

X is selected from (1) —O and (2) —CF 2

R a is selected from: (1) hydrogen and (2) C 1-4 alkyl;

each occurrence of R b is independently selected from: (1) hydrogen, (2) fluoro and (3) C 1-4 alkyl;

or alternatively, two R b groups on the same ring carbon form a spiro cyclopropyl;

or alternatively, two R b groups on adjacent ring carbons together with the two ring carbons form a fused cyclopropyl;

or alternatively, two R b groups on non-adjacent ring carbons together with the nitrogen ring atom form a 5-6 membered nitrogen-containing bridged heterocyclyl wherein the heterocyclyl contains no additional hetero atom;

R c is selected from: (1) hydrogen and (2) halogen;

R 3 and R 4 together with the nitrogen to which they are attached form a 5-6 membered heterocyclyl containing the one nitrogen to which they are attached and zero to one additional hetero atom independently selected from N, S and O, wherein the heterocyclyl is optionally substituted with one to four substituents independently selected from:

(a) halogen,

(b) —OH,

(c) C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH, (b) halogen and (c) —C(O)—NH 2 ,

(d) —O—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen

(e) —NHR f , wherein R f is selected from (i) hydrogen, (ii) methyl, (iii) ethyl and (iv) —C(O)—CH 3 , and

(f) —C(O)—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen; and

R 5 is selected from (1) carbocyclyl and (2) heterocyclyl,

wherein the carbocyclyl of (1) is selected from (a) C 3-6 cycloalkyl, (b) phenyl, (c) nathphyl and (d) 2,3-dihydro-1H-indenyl;

wherein the heterocyclyl of (2) is selected from furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, naphthyridinyl, phthalazinyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, quinazolinyl, isoquinolinyl and benzo[d]isothiazolyl; and

wherein each of the carbocyclyl and heterocyclyl is optionally substituted with one to three substituents independently selected from:

(a) halogen,

(b) C 1-4 alkyl, optionally substituted with one to four halogens,

(c) —O—C 1-4 alkyl, optionally substituted with one to four halogens and

(d) —CN.

11 . The compound of claim 10 , or a pharmaceutically acceptable salt thereof:

wherein:

n is 1;

X is selected from (1) and (2) —CF 2 ;

R a is hydrogen;

each occurrence of R b is independently selected from: (1) hydrogen, (2) fluoro, (3) methyl and (4) ethyl;

or alternatively, two R b groups on the same ring carbon form a spiro cyclopropyl;

or alternatively, two R b groups on adjacent ring carbons together with the two ring carbons form a fused cyclopropyl;

or alternatively, two R b groups on non-adjacent ring carbons together with the nitrogen ring atom form a 5-6 membered nitrogen-containing bridged heterocyclyl wherein the heterocyclyl contains no additional hetero atom;

R c is selected from: (1) hydrogen and (2) fluoro;

R 3 and R 4 together with the nitrogen to which they are attached form a 5-6 membered non-aromatic heterocyclyl containing the one nitrogen to which they are attached and zero to one additional hetero atom independently selected from N and O, wherein the heterocyclyl is optionally substituted with one to four substituents independently selected from:

(a) fluoro,

(b) —OH,

(c) C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH, (b) halogen and (c) —C(O)—NH 2 ,

(d) —O—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen

(e) —NHR f , wherein R f is selected from (i) hydrogen, (ii) methyl, (iii) ethyl and (iv) —C(O)—CH 3 , and

(f) —C(O)—C 1-4 alkyl, optionally substituted with one to three substituents independently selected from (a) —OH and (b) halogen; and

R 5 is selected from (1) carbocyclyl and (2) heterocyclyl,

wherein the carbocyclyl of (1) is selected from (a) C 3-6 cycloalkyl, (b) phenyl, (c) nathphyl and (d) 2,3-dihydro-1H-indenyl;

wherein the heterocyclyl of (2) is selected from (a) pyridinyl, (b) pyrimidinyl, (c) isoquinolinyl and (d) benzo[d]isothiazolyl; and

wherein each of the carbocyclyl and heterocyclyl is optionally substituted with one to three substituents independently selected from:

(a) halogen,

(b) methyl, optionally substituted with one to three halogens,

(c) —OCH 3 ,

(d) —OCF 3 and

(e) —CN.

12 . A compound selected from the group consisting of:

1-(4-(2-chlorophenoxy)piperidin-1-yl)-2-(3-(4-hydroxy-4-(hydroxymethyl)piperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

2-hydroxy-1-(4-((3bR,4aR)-1-(2-oxo-2-(4-(o-tolyloxy)piperidin-1-yl)ethyl)-3b,4, 4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carbonyl)piperazin-1-yl)ethanone,

1-[4-(2-chlorophenoxy)-1-piperidyl]-2-[3-(4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydroindazol-1-yl]ethanone,

1-((2R,4R)-4-(2-chlorophenoxy)-2-methylpiperidin-1-yl)-2-((3bR,4aR)-3-(4-(2-hydroxyacetyl)piperazine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

2-(4-(1-(2-(4-(2-chlorophenoxy)piperidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carbonyl)piperazin-1-yl)acetamide,

N-(1-(1-(2-(4-(2-chlorophenoxy)piperidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carbonyl)piperidin-4-yl)acetamide,

1-(4-(2-chlorophenoxy)piperidin-1-yl)-2-(3-((3R,4S)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

2-((3bR,4aR)-3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-1-((2R,4R)-2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)ethanone,

1-(4-(2-chlorophenoxy)piperidin-1-yl)-2-(3-((3S,4R)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

1-(4-(2-chlorophenoxy)piperidin-1-yl)-2-(3-(4-(2-hydroxyacetyl)piperazine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethan-1-one,

ethyl 1-(2-((2R,4R)-4-(2-chlorophenoxy)-2-methylpiperidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate,

2-hydroxy-1-(4-((3bR,4aR)-1-(2-((2R,4R)-2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carbonyl)piperazin-1-yl)ethanone,

(3bR,4aR)-ethyl 1-(2-((2R,4R)-2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate,

ethyl 1-(2-(4-(2-chlorophenoxy)piperidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate,

1-(4-(2-chlorophenoxy)piperidin-1-yl)-2-(3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

2-((3bR,4aR)-3-((3R,4S)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-((2S,4S)-4-hydroxy-2-methylpiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-(4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-((3bR,4aR)-3-(4-hydroxypiperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-(4-(difluoromethyl)-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-((3S,4S)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

N-(1-(1-(2-oxo-2-(4-(o-tolyloxy)piperidin-1-yl)ethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carbonyl)piperidin-4-yl)acetamide,

2-(3-(4-hydroxy-2,2-dimethylpiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-(4-(fluoromethyl)-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-((3bR,4aR)-3-((3S,4R)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-(4-fluoro-4-(hydroxymethyl)piperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

N-(1-((3bR,4aR)-1-(2-oxo-2-(4-(o-tolyloxy)piperidin-1-yl)ethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carbonyl)piperidin-4-yl)acetamide,

2-(3-(4-fluoro-4-(hydroxymethyl)piperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-((3R,4S)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-(4-hydroxypiperidine-1-carbonyl)-5,6,7,8-tetrahydrocyclohepta[c]pyrazol-1(4H)-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-(4-hydroxypiperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-((3S,4S)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-(4-(fluoromethyl)-4-hydroxypiperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-((3S,4R)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

(3bR,4aR)-ethyl 1-(2-oxo-2-(4-(o-tolyloxy)piperidin-1-yl)ethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate,

2-hydroxy-1-(4-(1-(2-oxo-2-(4-(o-tolyloxy)piperidin-1-yl)ethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carbonyl)piperazin-1-yl)ethanone,

2-(3-((3R,4S)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-(3-((3S,4R)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

1-(4-(3-chlorophenoxy)piperidin-1-yl)-2-(3-(4-fluoro-4-(hydroxymethyl)piperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

1-(4-(3-chlorophenoxy)piperidin-1-yl)-2-(3-((3S,4S)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

2-hydroxy-1-(4-(1-(2-oxo-2-(4-(o-tolyloxy)piperidin-1-yl)ethyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)piperazin-1-yl)ethanone,

1-(4-(3-chlorophenoxy)piperidin-1-yl)-2-(3-(4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

(R)-2-(3-(2-(hydroxymethyl)morpholine-4-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-(4-(o-tolyloxy)piperidin-1-yl)ethanone,

1-(4-(3-chlorophenoxy)piperidin-1-yl)-2-(3-(4-(fluoromethyl)-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

ethyl 1-(2-oxo-2-(4-(o-tolyloxy)piperidin-1-yl)ethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate,

1-(4-(3-chlorophenoxy)piperidin-1-yl)-2-(3-((3S,4R)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

ethyl 1-(2-oxo-2-(4-(o-tolyloxy)piperidin-1-yl)ethyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylate,

methyl 1-(2-oxo-2-(4-(o-tolyloxy)piperidin-1-yl)ethyl)-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-carboxylate,

ethyl 1-(2-(4-(3-chlorophenoxy)piperidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate,

1-((2R,4R)-4-(2-chlorophenoxy)-2-methylpiperidin-1-yl)-2-((3bR,4aR)-3-((3S,4R)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

1-((2R,4R)-4-(2-chlorophenoxy)-2-methylpiperidin-1-yl)-2-(3-(4-(2-hydroxyacetyl)piperazine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

1-((2S,4S)-4-((3-chloropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-((3bR,4aR)-3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

1-((2S,4S)-4-((3-chloropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-((3bR,4aR)-3-(4-hydroxypiperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

2-(3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-((2S,4R)-2-methyl-4-(o-tolyloxy)piperidin-1-yl)ethanone,

2-((3bR,4aR)-3-(4-hydroxypiperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-1-((2S,4R)-2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)ethanone,

1-((2R,4R)-4-((3-fluoropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-((3bR,4aR)-3-(4-hydroxypiperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

ethyl 1-(2-oxo-2-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)ethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate,

2-((3bR,4aR)-3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-1-((2S,4R)-2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)ethanone,

1-((2R,4R)-4-((3-fluoropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-((3bR,4aR)-3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

(S or R)-1-(7-((3-chloropyridin-2-yl)oxy)-4-azaspiro[2.5]octan-4-yl)-2-(3-(4-(2-hydroxy ethoxy)piperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

(R or S)-1-(7-((3-chloropyridin-2-yl)oxy)-4-azaspiro[2.5]octan-4-yl)-2-(3-(4-(2-hydroxy ethoxy)piperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

ethyl 1-(2-(7-((3-chloropyridin-2-yl)oxy)-4-azaspiro[2.5]octan-4-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate,

(S or R)-ethyl 1-(2-(7-((3-chloropyridin-2-yl)oxy)-4-azaspiro[2.5]octan-4-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate,

1-((2S,4R)-4-((3-chloropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-(3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)ethanone,

2-((3bR,4aR)-3-((3S,4R)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-1-((2S,4R)-2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)ethanone,

(3bR,4aR)-ethyl 1-(2-((2S,4S)-4-((3-chloropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate,

1-((S or R)-7-((3-chloropyridin-2-yl)oxy)-4-azaspiro[2.5]octan-4-yl)-2-(3-((3S,4R)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)ethanone,

1-((2S,4R)-4-((3-chloropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-(3-((3S,4R)-3-fluoro-4-hydroxypiperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)ethanone,

(3bR,4aR)-ethyl 1-(2-((2R,4R)-4-((3-fluoropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate,

(3bR,4aR)-ethyl 1-(2-((2S,4R)-2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate,

(3bR,4aR)-ethyl 1-(2-((2R,4R)-4-((3-chloropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate,

1-((2R,4R)-4-((3-chloropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-((3bR,4aR)-3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

1-((2R,4R)-4-((3-chloropyridin-2-yl)oxy)-2-methylpiperidin-1-yl)-2-((3bR,4aR)-3-(4-hydroxypiperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[4-(2-hydroxyethoxy)piperidine-1-carbonyl]-4,5,6,7-tetrahydroindazol-1-yl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[rac-(3R,4S)-3-fluoro-4-hydroxy-piperidine-1-carbonyl]-4,5,6,7-tetrahydroindazol-1-yl]ethanone,

2-[3-[4-fluoro-4-(hydroxymethyl)piperidine-1-carbonyl]-4,5,6,7-tetrahydroindazol-1-yl]-1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[4-(2-hydroxyacetyl)piperazine-1-carbonyl]-4,5,6,7-tetrahydroindazol-1-yl]ethanone,

2-[3-[4-fluoro-4-(hydroxymethyl)piperidine-1-carbonyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-1-yl]-1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[(2S)-2-(hydroxymethyl)morpholine-4-carbonyl]-4,5,6,7-tetrahydroindazol-1-yl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[(2R)-2-(hydroxymethyl)morpholine-4-carbonyl]-4,5,6,7-tetrahydroindazol-1-yl]ethanone,

2-[3-[4-fluoro-4-(hydroxymethyl)piperidine-1-carbonyl]-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-1-yl]-1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[4-(2-hydroxyacetyl)piperazine-1-carbonyl]-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-1-yl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[(2S)-2-(hydroxymethyl)morpholine-4-carbonyl]-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-1-yl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[(2R)-2-(hydroxymethyl)morpholine-4-carbonyl]-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-1-yl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[(2S)-2-(hydroxymethyl)morpholine-4-carbonyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-1-yl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[4-(2-hydroxyacetyl)piperazine-1-carbonyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-1-yl]ethanone,

1-[4-(4-fluoro-2-methyl-phenoxy)-1-piperidyl]-2-[3-[(2R)-2-(hydroxymethyl)morpholine-4-carbonyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-1-yl]ethanone,

2-(3-(cis-2,6-Dimethylmorpholine-4-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)-1-(4-(5-fluoro-2-methylphenoxy)piperidin-1-yl)ethan-1-one,

1-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(2-chlorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(2-chloro-5-methylphenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-{4-[(2,3-dihydro-1H-inden-5-yl)oxy]piperidin-1-yl}-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(4-methylphenoxy)piperidin-1-yl]ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}ethan-1-one,

1-[4-(4-bromophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(3-methylphenoxy)piperidin-1-yl]ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(3-fluorophenoxy)piperidin-1-yl]ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[2-(trifluoromethoxy)phenoxy]piperidin-1-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2-fluorophenoxy)piperidin-1-yl]ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-(4-phenoxypiperidin-1-yl)ethan-1-one,

1-[4-(3-chlorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(4-chlorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{[1-({3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}acetyl)piperidin-4-yl]oxy}benzonitrile,

1-[4-(3,4-difluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[(naphthalen-1-yl)oxy]piperidin-1-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-(4-{[3-(trifluoromethoxy)pyridin-2-yl]oxy}piperidin-1-yl)ethan-1-one,

4-{[1-({3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}acetyl)piperidin-4-yl]oxy}benzonitrile,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[2-(propan-2-yl)phenoxy]piperidin-1-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[3-(2-methylphenoxy)azetidin-1-yl]ethan-1-one,

1-[3-(2-chloro-6-fluorophenoxy)-8-azabicyclo[3.2.1]octan-8-yl]-2-[3-(4-hydroxypiperidine-1-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl]ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2-methylphenoxy)piperidin-1-yl]ethan-1-one,

1-[4-(2-chloro-4-fluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(benzyloxy)-3,3-difluoropiperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[3-(2-chlorophenoxy)pyrrolidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[3-(2-chlorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-{3-[(2,6-difluorophenyl)methoxy]pyrrolidin-1-yl}-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[3-(2-chlorophenoxy)pyrrolidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[3-(2-chlorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(3-fluoro-2-methylphenoxy)piperidin-1-yl]ethan-1-one,

1-{4-[(7-chloro-2,3-dihydro-1H-inden-4-yl)oxy]piperidin-1-yl}-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2,3-dimethylphenoxy)piperidin-1-yl]ethan-1-one,

1-[4-(2-chloro-4-methylphenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2-fluoro-4-methylphenoxy)piperidin-1-yl]ethan-1-one,

1-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(3-chloro-2-methylphenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-[3-(2,6-dimethylmorpholine-4-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl]-1-[4-(5-fluoro-2-methylphenoxy)piperidin-1-yl]ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(3,4-dimethylphenoxy)piperidin-1-yl]ethan-1-one,

1-[4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2-fluoro-6-methylphenoxy)piperidin-1-yl]ethan-1-one,

1-[4-(3-chloro-2-fluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(2-chloro-6-fluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(4-chloro-3-methylphenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(3-bromo-2-methylphenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(3-chloro-4-methylphenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2,3,5-trifluorophenoxy)piperidin-1-yl]ethan-1-one,

1-[4-(4-chloro-2-methylphenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(2,4-dichlorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2,6-dimethylphenoxy)piperidin-1-yl]ethan-1-one,

1-[4-(4-chloro-3-fluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(2,5-difluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2-fluoro-5-methylphenoxy)piperidin-1-yl]ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(4-fluoro-3-methylphenoxy)piperidin-1-yl]ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2,3,5-trimethylphenoxy)piperidin-1-yl]ethan-1-one,

1-[4-(2,6-difluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-[4-(4-chloro-2-fluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2,3,4-trifluorophenoxy)piperidin-1-yl]ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[(isoquinolin-5-yl)oxy]piperidin-1-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-[4-(2,4,6-trifluorophenoxy)piperidin-1-yl]ethan-1-one,

1-[4-(2-bromo-3-fluorophenoxy)piperidin-1-yl]-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-{4-[2-chloro-3-(trifluoromethyl)phenoxy]piperidin-1-yl}-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-{4-[2-chloro-5-(trifluoromethyl)phenoxy]piperidin-1-yl}-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

1-{4-[(1,2-benzothiazol-5-yl)oxy]piperidin-1-yl}-2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[(quinolin-6-yl)oxy]piperidin-1-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[2-fluoro-3-(trifluoromethyl)phenoxy]piperidin-1-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[(isoquinolin-7-yl)oxy]piperidin-1-yl}ethan-1-one,

2-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl}-1-{4-[3-(trifluoromethoxy)phenoxy]piperidin-1-yl}ethan-1-one,

1-(4-(Cyclopentyloxy)piperidin-1-yl)-2-(3-((2S,6R)-2,6-dimethylmorpholine-4-carbonyl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl)ethan-1-one,

1-(4-((3bR,4aR)-1-(2-(5-(2-Chlorophenoxy)-2-azabicyclo[4.1.0]heptan-2-yl)-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carbonyl)piperazin-1-yl)-2-hydroxyethanone,

1-(5-(2-Chlorophenoxy)-2-azabicyclo[4.1.0]heptan-2-yl)-2-((3bR,4aR)-3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

1-(4-((3bR,4aR)-1-(2-(5-(2-Chlorophenoxy)-2-azabicyclo[4.1.0]heptan-2-yl)-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carbonyl)piperazin-1-yl)-2-hydroxyethanone,

1-(5-(2-Chlorophenoxy)-2-azabicyclo[4.1.0]heptan-2-yl)-2-((3bR,4aR)-3-(4-(2-hydroxyethoxy)piperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)ethanone,

2-Hydroxy-1-(4-((3bR,4aR)-1-(2-oxo-2-(5-phenoxy-2-azabicyclo[4.1.0]heptan-2-yl)ethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carbonyl)piperazin-1-yl)ethanone,

2-((3bR,4aR)-3-(4-(2-Hydroxyethoxy)piperidine-1-carbonyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-1-(5-phenoxy-2-azabicyclo[4.1.0]heptan-2-yl)ethanone,

N-(1-(1-(2-(4-((3-Methylpyridin-2-yl)oxy)piperidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carbonyl)piperidin-4-yl)acetamide,

2-(3-(4-Hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(4-((3-methylpyridin-2-yl)oxy)piperidin-1-yl)ethanone, and

2-(3-(4-Hydroxypiperidine-1-carbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-1-(3-((3-methylpyridin-2-yl)oxy)-8-azabicyclo[3.2.1]octan-8-yl)ethan-1-one;

or a pharmaceutically acceptable salt thereof.

13 . A composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2021
From: CLAUSEN, DANE; FRADERA, XAVIER; GUO, LIANGQIN; HAN, YONGXIN; HE, SHUWEN; HUANG, XIANHAI; KOZLOWSKI, JOSEPH; LI, GUOQING; LIM, JONGWON; MARTINOT, THEODORE A.; PASTERNAK, ALEXANDER; SCIAMMETTA, NUNZIO; VERRAS, ANDREAS; XIAO, LI; YU, WENSHENG; ZHANG, RUI
To: MERCK SHARP & DOHME CORP.
Reel/Frame 055316/0387 →
Continuity (2)
Provisional Application 62721283 · Aug 22, 2018
Related Publication 20210330676A1 · Oct 28, 2021
References Cited (16)
US 12091405B2 · Clausen · 2024 [cited by examiner]
US 12152019B2 · Clausen · 2024 [cited by examiner]
US 20180186787A1 · Cowley et al. · 2018 [cited by applicant]
US 20230008022A1 · Clausen · 2023 [cited by examiner]
WO WO2008013925A2 · 2008 [cited by examiner]
WO 2017185959A1 · 2017 [cited by applicant]
WO WO2018160889A1 · 2018 [cited by examiner]
WO WO2018160891A1 · 2018 [cited by examiner]
WO 2020081381A1 · 2020 [cited by applicant]
WO 2020092183A1 · 2020 [cited by applicant]
WO 2020112581A1 · 2020 [cited by applicant]
Dolušić et al. Expert Opinion on Therapeutic Patents, 2013, 23:10, 1367-1381 “Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008—2012)”. (Year: 2013). [cited by examiner]
Röhrig et al. J. Med. Chem. 2010, 53, 1172-1189. “Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors”. (Year: 2010). [cited by examiner]
Cheong et al. Expert Opinion on Therapeutic Patents, 2018, vol. 28, No. 4, 317-330, “A patent review of IDO1 inhibitors for cancer”. (Year: 2018). [cited by examiner]
Röhrig et al. J. Med. Chem. 2015, 58, 9421-9437 DOI: 10.1021/acs.jmedchem.5b00326 Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors (Year: 2015). [cited by examiner]
Pubchem, Substance Record for SID 241430767, Available Date: Feb. 23, 2015. [retrieved on Nov. 18, 2019]. Retrieved from the Internet: https://pubchem.ncbi.nlm.nih.gov/substances/241430767. entire document. [cited by applicant]